Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.60 |
| ▸ | FAAH | O00519 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29698174 | 0.92 | HPGD (0.68) | MGLLFAAHTRPV1HPGDCYP1A2 | |
| SCHEMBL8247508 | 0.92 | HPGD (0.68) | MGLLFAAHTRPV1HPGDCYP1A2 | |
| SCHEMBL28958710 | 0.81 | GAA (0.56) | MGLLHPGDCYP1A2MEN1RAB9A | |
| SCHEMBL13647708 | 0.81 | HPGD (0.54) | MGLLFAAHTRPV1HPGDMEN1 | |
| SCHEMBL26042174 | 0.80 | CYP1A2 (0.69) | MGLLFAAHCYP1A2CYP2D6MEN1 | |
| SCHEMBL18424173 | 0.80 | CYP1A2 (0.73) | MGLLFAAHCYP1A2CYP2D6MEN1 | |
| SCHEMBL1734128 | 0.79 | MGLL (0.63) | MGLLFAAHHPGDCYP1A2CYP2D6 | |
| SCHEMBL31596882 | 0.79 | LIPE (0.58) | MGLLHPGDMEN1RAB9AKMT2A | |
| SCHEMBL640619 | 0.79 | CYP1A2 (0.76) | MGLLFAAHCYP1A2CYP2D6MEN1 | |
| SCHEMBL19675154 | 0.78 | ROCK1 (0.53) | MGLLMEN1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025109097-A2 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | NAMPT, NAPRT, NNMT | MGLL 3277/4885FAAH 3152/4885TRPV1 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.